Watch for new wave of mad cow: Masters
15 August, 2003 by Melissa TrudingerWhile the incidence of variant Creutzfeldt-Jakob disease (vCJD) -- the human form of mad cow disease -- appears to have slowed in the UK after 146 confirmed cases since the epidemic began in the mid-1990's, a new wave of cases could be waiting in the wings, according to Australian neuroscientist Prof Colin Masters.
AustCancer shuffles staff and direction
14 August, 2003 by Jeremy TorrAustralian Cancer Technology (AustCancer) has changed tack with new management, a new product line and a move from Perth to Sydney -- all in one day.
Neuro facility teams with UK firm to develop MND model
12 August, 2003 by Melissa TrudingerA commercial alliance has been formed between the National Neuroscience Facility (NNF) and UK company Danio Labs, to develop a zebrafish model for Motor Neurone Disease (MND) and other neurodegenerative diseases.
Cytopia to use Start grant in pulmonary disorder work
06 August, 2003 by Graeme O'NeillMelbourne biomedical company Cytopia has won a $1.7 million AusIndustry Start grant to develop treatments for chronic obstructive pulmonary disorder (COPD), a currently untreatable condition that affects more than 600 million people worldwide.
Metabolic to spend $2.1m grant on clinical trials
06 August, 2003 by Melissa TrudingerMetabolic Pharmaceuticals (ASX:MBP) has been granted an R&D Start grant of up to AUD$2.1 million to conduct its Phase IIb clinical trial for its obesity drug AOD9604.
WEHI's Vaux wins Victoria Prize
05 August, 2003 by Melissa TrudingerWalter and Eliza Hall Institute cancer researcher Dr David Vaux has been awarded the 2003 Victoria Prize for his pioneering work on the how, when and why of cell death.
Melbourne Uni student wins prestige award
31 July, 2003 by Jeremy TorrThe Swiss-based Serono Foundation has awarded a US$90,000 postgraduate fellowship grant to an ex-Melbourne Uni PhD to pursue research into cancer biology.
Qld start-up Thrombostat raises $800,000 in VC, grants
24 July, 2003 by Pete YoungBrisbane start-up company Thrombostat has attracted AUD$800,000 in venture capital and grants to develop drugs that could displace aspirin in long-term prevention and treatment of cardiovascular disease.
US backs down on health IP
22 July, 2003 by Jeremy TorrStrong negative reaction from local industry bodies has led to the US modifying plans to snare biotech IP by funding grants to Australian researchers.
Meditech starts anti-cancer clinical trial
15 July, 2003 by Jeremy TorrMeditech Research is to start clinical trials on its HyCAMP anti-cancer compound, targeting colorectal tumours in patients at the Centre for the Development of Cancer Therapeutics in Melbourne.
Bionomics takes a bite of Big Apple bank
14 July, 2003 by Melissa TrudingerBionomics has entered into a standby equity facility with an affiliate of the Bank of New York, allowing the company to sell up to six million shares through the affiliate group over the next three years.
Pathologists back down from GTG attack
11 July, 2003 by Melissa TrudingerThe Royal College of Pathologists of Australasia (RCPA) and associated genetics organisations, including the Human Genetics Society of Australia, have retracted and clarified recent statements made in a letter to state and Federal government officials, which suggested that Melbourne biotech company Genetic Technologies would seek to enforce the breast cancer gene patents licensed to it by Myriad Genetics.
Benefits outweigh gene therapy risks
09 July, 2003 by Melissa TrudingerThe risks of developing cancer as a side-effect of gene therapy were outweighed by the potential benefit to the patients, one of the scientists involved in gene therapy clinical trials said yesterday at the XIX International Congress of Genetics.
Panbio scores FDA approval, world first
09 July, 2003 by Jeremy TorrBribane diagnostic biotech Panbio has become the first company ever to rate US FDA approval for a West Nile virus (WNV) immunoassay diagnostic kit.
BioFirst lures researchers
09 July, 2003 by Jeremy TorrNSW’s BioFirst awards have attracted two top overseas researchers to the state, in the first of this year’s appointments for overseas experts.
